Telix Receives the US FDA’s Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)

 Telix Receives the US FDA’s Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)

Telix Receives the US FDA’s Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)

Shots:

  • The US FDA has granted BTD for Telix’s renal cancer imaging product TLX250-CDx (89Zr-girentuximab)
  • Under BTD, the FDA will work closely with Telix to provide guidance on the development of TLX250-CDx for the diagnosis of “indeterminate renal masses” that have been identified on CT or MRI imaging
  • TLX250-CDx is being developed for the purpose of determining “indeterminate renal masses” are either ccRCC or non-ccRCC, using PET imaging

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post